Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis
- 遲發報告將展示VANTAGE研究評估volixibat在原發性膽汁性膽管炎中的數據
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting, taking place November 15-19, 2024, in San Diego, California.
Mirum Pharmaceuticals, Inc.（納斯達克：MIRM）今天宣佈，將在美國肝病研究協會（AASLD）舉行的肝臟會議上發佈數據，該會議將於2024年11月15日至19日在加利福尼亞州聖地亞哥舉行。
Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the AASLD website. Full analyses will be available following their presentation within the Publications & Presentation section on Mirum's website.
以下是會議期間接受報告的標題。摘要可通過AASLD網站獲取。完整分析將在Mirum網站的出版物與報告部分的展示後提供。
譯文內容由第三人軟體翻譯。
